MedTrace Logo

Quality of Life in Normogonadotropic Anovulation

NCT06208995 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 990

Last updated 2026-03-19

No results posted yet for this study

Summary

Among the causes of ovulation disorders (group II of anovulation according to the World Health Organization classification), the dominant one is polycystic ovary syndrome (PCOS), and the remaining cases are classified as Hypothalamic-Pituitary-Ovarian Axis Dysfunction (HPOD). The exact etiology of both entities is unknown. To diagnose PCOS, the Rotterdam criteria must be met and other conditions that may cause hyperandrogenism or ovulation disorders must be excluded. PCOS is more often accompanied by other endocrine and metabolic disorders, such as obesity, dyslipidemia, hyperandrogenism, insulin resistance, diabetes, hyperprolactinemia and thyroid diseases, as well as infertility due to ovulation defect. These conditions not only significantly reduce quality of life (QoL), but also lead to an increased risk of cardiovascular disease, metabolic syndrome, adverse obstetric outcomes and an increased risk of endometrial cancer, further impairing QoL.

Conditions

  • Anovulation
  • Irregular Menses

Interventions

OTHER

36-Item Short Form Survey Instrument (SF-36)

Answering 36 questions in a quality-of-life survey (RAND 36-Item Health Survey 1.0): https://www.rand.org/health-care/surveys\_tools/mos/36-item-short-form/survey-instrument.html

Sponsors & Collaborators

  • Jagiellonian University

    lead OTHER

Principal Investigators

  • Robert Jach, Prof., PhD · Jagiellonian University

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2024-12-01
Completion
2024-12-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06208995 on ClinicalTrials.gov